Department of Obstetrics and Gynecology, Army Hospital (Research & Referral), New Delhi, India.
Int J Gynecol Cancer. 2010 Aug;20(6):1041-5. doi: 10.1111/IGC.0b013e3181dcadeb.
Posttreatment morbidity of multimodality therapy is substantially higher than either radical surgery or chemoradiation alone. Preoperative prediction of positive nodes limits optimal selection of the primary treatment modality. Computed tomography (CT) and magnetic resonance imaging have been tried for nodal assessment with modest results. Positron emission tomography (PET) combined with CT seems to be promising in this regard. This clinicopathologic study assesses the value of PET-CT in predicting nodal metastasis and avoiding multimodality therapy.
Eighty patients with clinically operable cervical cancer underwent PET-CT during the preoperative evaluation followed by radical hysterectomy. Adjuvant chemoradiation was administered when indicated by histopathologic findings. The histopathologic finding of the pelvic nodes was correlated with the PET-CT findings for nodal metastasis. The chi2 test was used as the test of significance in the statistical analysis.
Of 62 patients found PET-CT negative for nodal disease, 52 were true negative, whereas 10 were false negative on histopathologic examination. On the other hand, 14 of 18 patients found PET-CT positive for nodal disease were true positives. Specificity, sensitivity, positive predictive value, and negative predictive value of PET-CT in nodal assessment were found to be 92.8, 58.33, 77.7, and 83.8, respectively. Twenty-four patients (30%) with pelvic nodes positive for disease on histopathologic examination were administered adjuvant chemoradiation. Had we operated only on those patients who were PET-CT negative for nodal disease, 10 of 62 patients would have required adjuvant chemoradiation for positive nodes. Eighteen patients found PET-CT positive for nodal disease would be treated with primary chemoradiation. Inclusion of PET-CT in the decision-making process for primary surgery versus primary chemoradiation would allow 87.5% patients to receive a single modality of treatment (65%, only surgery; 22.5%, only chemoradiation) and the proportion of patients requiring multimodality treatment would reduce significantly from 30% to 12.5% (P < 0.01).
Positron emission tomography combined with CT in the evaluation of operable cervical cancer can help in the optimal selection of patients for surgery such that multimodality treatment with its attendant increase in morbidity is avoided.
多模式治疗的治疗后发病率明显高于根治性手术或放化疗。术前预测阳性淋巴结可限制对主要治疗方式的最佳选择。计算机断层扫描(CT)和磁共振成像(MRI)已被尝试用于淋巴结评估,但结果并不理想。正电子发射断层扫描(PET)结合 CT 在这方面似乎很有前途。本临床病理研究评估了 PET-CT 在预测淋巴结转移和避免多模式治疗中的价值。
80 例临床可手术的宫颈癌患者在术前评估期间接受了 PET-CT 检查,随后进行根治性子宫切除术。根据组织病理学检查结果,给予辅助放化疗。盆腔淋巴结的组织病理学发现与 PET-CT 对淋巴结转移的发现相关。在统计分析中,使用卡方检验作为显著性检验。
62 例 PET-CT 检查淋巴结阴性的患者中,52 例为真阴性,而 10 例为假阴性。另一方面,18 例 PET-CT 检查淋巴结阳性的患者中,14 例为真阳性。在淋巴结评估中,PET-CT 的特异性、敏感性、阳性预测值和阴性预测值分别为 92.8%、58.33%、77.7%和 83.8%。24 例(30%)盆腔淋巴结阳性的患者接受了辅助放化疗。如果我们只对那些 PET-CT 检查淋巴结阴性的患者进行手术,那么在 62 例患者中,将有 10 例需要接受辅助放化疗以治疗阳性淋巴结。18 例 PET-CT 检查淋巴结阳性的患者将接受以放化疗为主的治疗。将 PET-CT 纳入主要手术与主要放化疗的决策过程中,可以使 87.5%的患者接受单一模式的治疗(65%仅手术;22.5%仅放化疗),并且需要多模式治疗的患者比例将从 30%显著降低至 12.5%(P<0.01)。
在可手术宫颈癌的评估中,正电子发射断层扫描(PET)结合 CT 有助于为患者选择最佳手术方案,从而避免多模式治疗及其伴随的发病率增加。